Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices)
- PMID: 34448829
- PMCID: PMC9071523
- DOI: 10.1093/ehjqcco/qcab059
Improved clinical investigation and evaluation of high-risk medical devices: the rationale and objectives of CORE-MD (Coordinating Research and Evidence for Medical Devices)
Abstract
In the European Union (EU) the delivery of health services is a national responsibility but there are concerted actions between member states to protect public health. Approval of pharmaceutical products is the responsibility of the European Medicines Agency, whereas authorizing the placing on the market of medical devices is decentralized to independent 'conformity assessment' organizations called notified bodies. The first legal basis for an EU system of evaluating medical devices and approving their market access was the medical device directives, from the 1990s. Uncertainties about clinical evidence requirements, among other reasons, led to the EU Medical Device Regulation (2017/745) that has applied since May 2021. It provides general principles for clinical investigations but few methodological details-which challenges responsible authorities to set appropriate balances between regulation and innovation, pre- and post-market studies, and clinical trials and real-world evidence. Scientific experts should advise on methods and standards for assessing and approving new high-risk devices, and safety, efficacy, and transparency of evidence should be paramount. The European Commission recently awarded a Horizon 2020 grant to a consortium led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, that will review methodologies of clinical investigations, advise on study designs, and develop recommendations for aggregating clinical data from registries and other real-world sources. The CORE-MD project (Coordinating Research and Evidence for Medical Devices) will run until March 2024; here we describe how it may contribute to the development of regulatory science in Europe.
Keywords: Clinical investigations; Evidence-based practice; Medical devices; Registries.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Figures


References
-
- European Union . Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2017.11....
-
- Fraser AG, Butchart EG, Szymański P, Caiani EG, Crosby S, Kearney P et al. The need for transparency of clinical evidence for medical devices in Europe. Lancet 2018;392:521‒530. - PubMed
-
- Commission Staff Working Document Impact Assessment on the Revision of the Regulatory Framework for Medical Devices, accompanying the documents Proposals for Regulations of the European Parliament and of the Council on medical devices, and amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and on in vitro diagnostic medical devices. SWD/2012/0273 final. https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:52012SC0273 (16 June 2021).
-
- European Commission . SC1-HCO-18-2020: developing methodological approaches for improved clinical investigation and evaluation of high-risk medical devices. https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/op... (17 May 2021).